AgriMetis Announces Publication of Additional SpinoMetis Patent Applications

LUTHERVILLE, MD – August 4, 2018 – AgriMetis™, LLC is pleased to announce that a fifth international patent application covering its insecticide portfolio of novel SpinoMetis™ spinosyn analogs has published. In March 2018, Monsanto Company (now a part of Bayer AG) and AgriMetis announced an exclusive collaboration for Monsanto’s continued research with AgriMetis’ SpinoMetis platform, and the compounds exemplified in this application are included in that collaboration. “The novel compounds described in AgriMetis’ numerous SpinoMetis-related applications show strong performance, and we look forward to working with the Bayer and Monsanto team to advance them through the development process,” said Brian Green, AgriMetis’ VP of Research and Development. With this addition to its growing patent portfolio, AgriMetis continues to progress toward delivering commercially viable products to the agricultural crop protection industry through an extensive and expanding research and development pipeline. For more information on this PCT publication, a link is provided below:

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018132288

 About AgriMetis:

In an evolving and growing global population, there continues to be an increasing demand for sustainable, crop protection products. AgriMetis is committed to working with leading agriculture companies and businesses to fill this emerging need.

Our mission is to innovate sustainable crop protection products through leading edge and advanced discovery, development and delivery methods.

The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry. AgriMetis’ scientific approach is multidisciplinary and integrated, which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others.

AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities.

For more information, please visit our website at http://www.agrimetis.com

This press release contains “forward-looking statements” concerning the development of AgriMetis’ products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.

Laurie Gunther